Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome-Reference-Cited by-同舟云学术

Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome

Published:2021-02-28 Issue:5 Volume:20 Page:561-576
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Nabbout Rima¹²^ORCID,Chemaly N¹²,Chiron C¹³^ORCID,Kuchenbuch M.¹²^ORCID

Affiliation:

1. Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker Enfants Malades University Hospital, Université De Paris, Paris, France

2. Institut National De La Santé Et De La Recherche Médicale (INSERM), UMR 1163, Institut Imagine, Université De Paris, Paris, France

3. INSERM U1141, Paris, France & Neurospin, CEA, Gif/Yvette, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1890025

Reference132 articles.

1. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen

2. The European Commission. Communication from the commission—guideline on aspects of the application of article 8(2) of regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products [Internet]. 2008 [cited 2021 Feb 19. Available from: https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:242:0008:0011:EN:PDF.

3. US Food and Drug Administration. Developing products for rare diseases [internet]. off. comm. 2017 [cited 2021 Feb 19]. p. 8–9. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2C207223Orig1s000MedR.pdf.

4. The core Dravet syndrome phenotype

5. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fenfluramine below the age of 2 years in Dravet syndrome: What about safety and efficacy?;Epilepsia;2023-12-21

2. Dravet syndrome: A systematic literature review of the illness burden;Epilepsia Open;2023-10-11

3. A review of emerging micro-pollutants in hospital wastewater: Environmental fate and remediation options;Results in Engineering;2022-12

4. Stiripentol Enteric Solid Dispersion-Loaded Effervescent Tablets: Enhanced Dissolution, Stability, and Absorption;AAPS PharmSciTech;2022-05-10

5. Recent Advances on the Aqueous Phase Adsorption of Carbamazepine;ChemBioEng Reviews;2022-01-19